Evolution of the Average Target: Fate Therapeutics, Inc.

Evolution of the Target Price: Fate Therapeutics, Inc.

Changes in Analyst Recommendations: Fate Therapeutics, Inc.

b2497f1a16b3498f3f78.EzLlHUcwLPzLwSmEfLEOPiMrJGF0eTmMi8SnX5ztx3k.IEuzeQ1pe8ynt1PsPutRVBBdfBstEEO8svL3OvWClTt8R6oscnVtqK6lTg~d9c2b361794b6a9e425cfd65d03ca904
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
11-13 Fate Therapeutics Q3 net loss widens RE
31/10/25 Fate Therapeutics Shares Rise After HC Wainwright Upgrade MT
31/10/25 HC Wainwright Upgrades Fate Therapeutics to Buy From Neutral, $5 Price Target MT
27/10/25 Wedbush Upgrades Fate Therapeutics to Outperform From Neutral, Raises Price Target to $7 From $5 MT
02/10/25 Fate Therapeutics reports new employee inducement awards under Nasdaq listing rule RE
15/08/25 BofA Securities Adjusts Fate Therapeutics Price Target to $2 From $2.20, Maintains Neutral Rating MT
19/11/24 BofA Securities Upgrades Fate Therapeutics to Neutral From Underperform, $3 Price Target MT
17/06/24 Piper Sandler Upgrades Fate Therapeutics to Overweight From Neutral, Adjusts Price Target to $6 From $4 MT
10/05/24 Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating MT
10/05/24 Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating MT
27/02/24 Morgan Stanley Raises Fate Therapeutics Price Target to $7 From $3, Maintains Equalweight Rating MT
27/02/24 BMO Capital Adjusts Price Target on Fate Therapeutics to $7 From $6, Maintains Market Perform Rating MT
27/02/24 Barclays Adjusts Price Target on Fate Therapeutics to $10 From $6, Maintains Overweight Rating MT
27/02/24 Wedbush Raises Fate Therapeutics' Price Target to $7 From $3, Keeps Neutral Rating MT
20/11/23 Mizuho Lowers Price Target on Fate Therapeutics to $8 From $12, Maintains Buy Rating MT
13/11/23 Morgan Stanley Adjusts Price Target on Fate Therapeutics to $3 From $5, Maintains Equalweight Rating MT
09/11/23 Wells Fargo Trims Price Target on Fate Therapeutics to $5 From $6, Maintains Equalweight Rating MT
09/11/23 Wedbush Lowers Fate Therapeutics' Price Target to $3 From $6, Maintains Neutral Rating MT
10/08/23 Morgan Stanley Adjusts Price Target on Fate Therapeutics to $5 From $8, Keeps Equalweight Rating MT
10/08/23 Barclays Adjusts Fate Therapeutics Price Target to $6 From $12, Maintains Overweight Rating MT
09/08/23 BMO Capital Adjusts Price Target on Fate Therapeutics to $5.40 From $6, Maintains Market Perform Rating MT
09/08/23 Wedbush Trims Fate Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating MT
04/05/23 Cantor Fitzgerald Adjusts Price Target on Fate Therapeutics to $5 From $8, Maintains Neutral Rating MT
04/05/23 Stifel Nicolaus Adjusts Fate Therapeutics Price Target to $5 From $5.30, Maintains Hold Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+122.65%
+11.45%
+20.14%
+10.58%
+65.16%
+17.73%
+1.06%
+26.41%
+20.45%
-7.67%
Average +28.80%
Weighted average by Cap. +18.53%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
2.580USD
Average target price
5.744USD
Spread / Average Target
+122.65%
High Price Target
8.000USD
Spread / Highest target
+210.08%
Low Price Target
2.200USD
Spread / Lowest Target
-14.73%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FATE Stock
  4. Consensus Fate Therapeutics, Inc.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!